StockData
Beam Therapeutics Inc. logo

Beam Therapeutics Inc. (BEAM) stock

BEAMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3012% below fair value
$20.65−0.29 (-1.38%)

Close on Nov 17, 2026Market cap $2.13BP/E –Yield –

Beam Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

No pe ratio figures for Beam Therapeutics

Beam Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Beam Therapeutics figures

See a number that looks wrong?